JP2015514811A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514811A5 JP2015514811A5 JP2015509201A JP2015509201A JP2015514811A5 JP 2015514811 A5 JP2015514811 A5 JP 2015514811A5 JP 2015509201 A JP2015509201 A JP 2015509201A JP 2015509201 A JP2015509201 A JP 2015509201A JP 2015514811 A5 JP2015514811 A5 JP 2015514811A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- eev
- library
- immunoglobulin
- vaccinia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 44
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 44
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 44
- 239000002157 polynucleotide Substances 0.000 claims description 37
- 102000040430 polynucleotide Human genes 0.000 claims description 37
- 108091033319 polynucleotide Proteins 0.000 claims description 37
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 25
- 239000000427 antigen Substances 0.000 claims description 21
- 102000036639 antigens Human genes 0.000 claims description 21
- 108091007433 antigens Proteins 0.000 claims description 21
- 208000007089 vaccinia Diseases 0.000 claims description 21
- 108020001507 fusion proteins Proteins 0.000 claims description 20
- 102000037865 fusion proteins Human genes 0.000 claims description 20
- 108060003951 Immunoglobulin Proteins 0.000 claims description 19
- 102000018358 immunoglobulin Human genes 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 241000700618 Vaccinia virus Species 0.000 claims description 17
- 108010052285 Membrane Proteins Proteins 0.000 claims description 15
- 102000018697 Membrane Proteins Human genes 0.000 claims description 15
- 230000004927 fusion Effects 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 239000013598 vector Substances 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 10
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims description 8
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 8
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 8
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 7
- 230000003834 intracellular effect Effects 0.000 claims description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 3
- 238000011144 upstream manufacturing Methods 0.000 claims description 3
- 102220477045 Dynein axonemal assembly factor 10_A56R_mutation Human genes 0.000 claims 8
- 101150039660 HA gene Proteins 0.000 claims 8
- 101150073066 F13L gene Proteins 0.000 claims 2
- 102220465562 Putative uncharacterized protein OBSCN-AS1_F13L_mutation Human genes 0.000 claims 2
- 101100502046 Vaccinia virus (strain Western Reserve) VACWR052 gene Proteins 0.000 claims 2
- 101100502047 Variola virus (isolate Human/India/Ind3/1967) C17L gene Proteins 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 1
- 239000013600 plasmid vector Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261639046P | 2012-04-26 | 2012-04-26 | |
| US61/639,046 | 2012-04-26 | ||
| US201261732776P | 2012-12-03 | 2012-12-03 | |
| US61/732,776 | 2012-12-03 | ||
| US13/844,388 US9708601B2 (en) | 2012-04-26 | 2013-03-15 | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US13/844,388 | 2013-03-15 | ||
| PCT/US2013/038497 WO2013163602A1 (en) | 2012-04-26 | 2013-04-26 | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018206485A Division JP2019055956A (ja) | 2012-04-26 | 2018-11-01 | 特異的免疫グロブリン遺伝子組み換えワクシニアウイルスに感染している細胞の選択を容易にするための融合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015514811A JP2015514811A (ja) | 2015-05-21 |
| JP2015514811A5 true JP2015514811A5 (enExample) | 2016-06-16 |
| JP6498599B2 JP6498599B2 (ja) | 2019-04-10 |
Family
ID=49477810
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015509201A Active JP6498599B2 (ja) | 2012-04-26 | 2013-04-26 | 特異的免疫グロブリン遺伝子組み換えワクシニアウイルスに感染している細胞の選択を容易にするための融合タンパク質 |
| JP2018206485A Withdrawn JP2019055956A (ja) | 2012-04-26 | 2018-11-01 | 特異的免疫グロブリン遺伝子組み換えワクシニアウイルスに感染している細胞の選択を容易にするための融合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018206485A Withdrawn JP2019055956A (ja) | 2012-04-26 | 2018-11-01 | 特異的免疫グロブリン遺伝子組み換えワクシニアウイルスに感染している細胞の選択を容易にするための融合タンパク質 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9708601B2 (enExample) |
| EP (1) | EP2841606B1 (enExample) |
| JP (2) | JP6498599B2 (enExample) |
| KR (1) | KR102108589B1 (enExample) |
| CN (1) | CN104520444B (enExample) |
| AU (1) | AU2013251371B2 (enExample) |
| CA (1) | CA2871597C (enExample) |
| DK (1) | DK2841606T3 (enExample) |
| EA (1) | EA028164B1 (enExample) |
| ES (1) | ES2725673T3 (enExample) |
| IL (1) | IL235323B (enExample) |
| NZ (1) | NZ630854A (enExample) |
| PL (1) | PL2841606T3 (enExample) |
| PT (1) | PT2841606T (enExample) |
| SG (1) | SG11201406974YA (enExample) |
| WO (1) | WO2013163602A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2427212T3 (pl) | 2009-05-08 | 2018-02-28 | Vaccinex, Inc. | Przeciwciała anty cd-100 i sposoby ich zastosowania |
| EA029023B1 (ru) | 2011-10-11 | 2018-01-31 | Вэксинекс, Инк. | Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| SG10201902380SA (en) | 2013-06-25 | 2019-04-29 | Vaccinex Inc | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| EP3107567A4 (en) * | 2014-02-19 | 2017-10-25 | Cangene Corporation | Methods of modulating an immune response |
| KR20170019080A (ko) | 2015-08-11 | 2017-02-21 | 주식회사 엘티전자 | 플렉시블 사이니지 장치 |
| EP3402520A4 (en) * | 2016-01-14 | 2019-01-02 | BPS Bioscience, Inc. | Anti-pd-1 antibodies and uses thereof |
| EP4059516A1 (en) * | 2016-04-22 | 2022-09-21 | Vaccinex, Inc. | Integral membrane protein display on poxvirus extracellular enveloped virions |
| SG11201900595YA (en) | 2016-08-02 | 2019-02-27 | Vaccinex Inc | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
| IL270244B2 (en) | 2017-05-05 | 2025-01-01 | Vaccinex Inc | Antibody against human semaphorin 4D |
| IL297578A (en) * | 2020-05-06 | 2022-12-01 | Vaccinex Inc | Integral membrane protein display on extracellular enveloped poxviruses |
| US20240148903A1 (en) * | 2021-03-08 | 2024-05-09 | Nanjing GenScript Biotech Co., Ltd. | Delivery of antibody by using dual viral vector system |
| KR20250022808A (ko) | 2022-06-10 | 2025-02-17 | 백시넥스 인코포레이티드 | 복합 막 항원에 특이적인 항체를 선택하는 방법 |
| WO2025184411A1 (en) | 2024-02-27 | 2025-09-04 | Calidi Biotherapeutics (Nevada), Inc. | Serum-resistant eev viruses and uses thereof |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5445953A (en) | 1991-08-26 | 1995-08-29 | Immuno Aktiengesellschaft | Direct molecular cloning of a modified poxvirus genome |
| AU694519B2 (en) | 1994-04-29 | 1998-07-23 | Immuno Aktiengesellschaft | Recombinant poxviruses with foreign polynucleotides in essential regions |
| US6576754B2 (en) | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
| US6872518B2 (en) | 1997-09-22 | 2005-03-29 | University Of Rochester | Methods for selecting polynucleotides encoding T cell epitopes |
| ATE407206T1 (de) | 1998-11-10 | 2008-09-15 | Univ Rochester | Methoden zu herstellung von genbanken |
| JP2003528605A (ja) | 2000-03-28 | 2003-09-30 | ユニヴァーシティー オヴ ロチェスター | ライブラリーを作成する方法および目的のポリヌクレオチドを選択する方法 |
| CA2341356C (en) | 2000-04-14 | 2011-10-11 | Transgene S.A. | Poxvirus with targeted infection specificity |
| CA2429544C (en) * | 2000-11-17 | 2010-10-19 | University Of Rochester | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
| WO2002062822A2 (en) | 2001-02-02 | 2002-08-15 | University Of Rochester | Methods of identifying regulator molecules |
| US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
| EP1413316A1 (en) | 2002-09-27 | 2004-04-28 | Bruno Robert | Bifunctional conjugates or fusion proteins |
| EP1442749A1 (en) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| CA2548180C (en) | 2003-12-04 | 2014-02-04 | Vaccinex, Inc. | Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells |
| US20050266425A1 (en) | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
| US8022043B2 (en) | 2004-08-27 | 2011-09-20 | Albert Einstein College Of Medicine Of Yeshiva University | Ceramide derivatives as modulators of immunity and autoimmunity |
| KR101377116B1 (ko) | 2004-08-27 | 2014-03-24 | 알버트 아인슈타인 컬리지 오브 메디신 오브 예쉬바 유니버시티 | 면역 및 자가면역의 조절제로서의 세라마이드 유도체 |
| US7858599B2 (en) | 2005-12-30 | 2010-12-28 | Hander Robert W | Enhancement of urogenital function |
| US9382327B2 (en) | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
| DE602008004296D1 (de) | 2007-02-14 | 2011-02-17 | Vaccinex Inc | Humanisierte anti-cd100-antikörper |
| JP5357782B2 (ja) | 2007-02-21 | 2013-12-04 | バクシネックス インコーポレーティッド | 抗原負荷ＣＤ１ｄ分子によるＮＫＴ細胞活性の調節 |
| JP5690593B2 (ja) | 2007-12-26 | 2015-03-25 | ヴァクシネックス， インコーポレイテッド | 抗ｃ３５抗体併用療法および方法 |
| AU2009303788B2 (en) * | 2008-05-28 | 2015-02-05 | Inovio Pharmaceuticals, Inc. | Smallpox DNA vaccine and the antigens therein that elicit an immune response |
| US20100081575A1 (en) | 2008-09-22 | 2010-04-01 | Robert Anthony Williamson | Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules |
| AU2010203451B2 (en) | 2009-01-08 | 2016-06-30 | Albert Einstein College Of Medicine, Inc. | Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof |
| PL2427212T3 (pl) | 2009-05-08 | 2018-02-28 | Vaccinex, Inc. | Przeciwciała anty cd-100 i sposoby ich zastosowania |
| WO2011110642A2 (en) * | 2010-03-10 | 2011-09-15 | Genmab A/S | Monoclonal antibodies against c-met |
| TW201134488A (en) * | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| SMT201900074T1 (it) * | 2010-05-04 | 2019-02-28 | Five Prime Therapeutics Inc | Anticorpi che legano csf1r |
| US8481688B2 (en) * | 2010-05-11 | 2013-07-09 | Aveo Pharmaceuticals, Inc. | Anti-FGFR2 antibodies |
| AU2011267869A1 (en) | 2010-06-14 | 2013-01-10 | Vaccinex, Inc. | Anti-VEGF antibodies and uses thereof |
| EP2404936A1 (en) * | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| US8603478B2 (en) * | 2010-07-06 | 2013-12-10 | Aveo Pharmaceuticals, Inc. | Anti-RON antibodies |
| EP2591090A4 (en) | 2010-07-07 | 2013-12-25 | Einstein Coll Med | BACTERIAL VACCINES ASSOCIATED WITH CERAMIDE GLYCOLIPIDS AND USES THEREOF |
| EP2611832B1 (en) | 2010-09-02 | 2017-11-29 | Vaccinex, Inc. | Anti-cxcl13 antibodies and methods of using the same |
| PT2711023T (pt) | 2011-05-13 | 2017-10-02 | Univ Nat Corp Tokyo Medical & Dental | Promotor da osteogénese |
| EA029023B1 (ru) | 2011-10-11 | 2018-01-31 | Вэксинекс, Инк. | Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера |
| US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
| CN104520323B (zh) | 2012-03-02 | 2018-05-04 | 瓦西尼斯公司 | 用于治疗b细胞介导的炎性疾病的方法 |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| JP6363623B2 (ja) | 2013-01-31 | 2018-07-25 | ヴァクシネックス， インコーポレイテッド | 免疫グロブリンａのレベルを増大するための方法 |
| US9371352B2 (en) | 2013-02-08 | 2016-06-21 | Vaccinex, Inc. | Modified glycolipids and methods of making and using the same |
| SG10201902380SA (en) | 2013-06-25 | 2019-04-29 | Vaccinex Inc | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| EP4059516A1 (en) | 2016-04-22 | 2022-09-21 | Vaccinex, Inc. | Integral membrane protein display on poxvirus extracellular enveloped virions |
| SG11201900595YA (en) | 2016-08-02 | 2019-02-27 | Vaccinex Inc | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
| WO2018156509A1 (en) | 2017-02-22 | 2018-08-30 | Vaccinex, Inc. | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
| US11572408B2 (en) | 2017-03-20 | 2023-02-07 | Vaccinex, Inc. | Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent |
| IL270244B2 (en) | 2017-05-05 | 2025-01-01 | Vaccinex Inc | Antibody against human semaphorin 4D |
-
2013
- 2013-03-15 US US13/844,388 patent/US9708601B2/en active Active
- 2013-04-26 PT PT13780660T patent/PT2841606T/pt unknown
- 2013-04-26 EA EA201491965A patent/EA028164B1/ru not_active IP Right Cessation
- 2013-04-26 PL PL13780660T patent/PL2841606T3/pl unknown
- 2013-04-26 CN CN201380033060.7A patent/CN104520444B/zh not_active Expired - Fee Related
- 2013-04-26 ES ES13780660T patent/ES2725673T3/es active Active
- 2013-04-26 EP EP13780660.0A patent/EP2841606B1/en active Active
- 2013-04-26 NZ NZ630854A patent/NZ630854A/en unknown
- 2013-04-26 KR KR1020147033046A patent/KR102108589B1/ko active Active
- 2013-04-26 AU AU2013251371A patent/AU2013251371B2/en active Active
- 2013-04-26 DK DK13780660.0T patent/DK2841606T3/da active
- 2013-04-26 CA CA2871597A patent/CA2871597C/en active Active
- 2013-04-26 SG SG11201406974YA patent/SG11201406974YA/en unknown
- 2013-04-26 JP JP2015509201A patent/JP6498599B2/ja active Active
- 2013-04-26 WO PCT/US2013/038497 patent/WO2013163602A1/en not_active Ceased
-
2014
- 2014-10-23 IL IL235323A patent/IL235323B/en active IP Right Grant
-
2015
- 2015-12-21 US US14/977,067 patent/US9701958B2/en active Active
-
2017
- 2017-06-12 US US15/619,790 patent/US10662422B2/en active Active
-
2018
- 2018-11-01 JP JP2018206485A patent/JP2019055956A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501535A5 (enExample) | ||
| JP2017514522A5 (enExample) | ||
| JP2019521643A5 (enExample) | ||
| JP2012143232A5 (enExample) | ||
| JP2019514367A5 (enExample) | ||
| JP2014531205A5 (enExample) | ||
| RU2014144143A (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток | |
| FI3596116T3 (fi) | Immunomodulatorisia pd-l1-varianttiproteiineja ja niiden käyttöjä | |
| FI3445397T3 (fi) | Integraalisen membraaniproteiinin näyttö poxviruksen solunulkoisilla vaipallisilla virioneilla | |
| JP2021534770A5 (enExample) | ||
| JP2020529841A5 (enExample) | ||
| JP2014534207A5 (enExample) | ||
| HRP20210874T1 (hr) | Imunomodulatorni proteini s prilagodljivim afinitetima | |
| WO2007130455A3 (en) | Compositions and methods for treatment of non-hodgkins lymphoma | |
| JP2016521539A5 (enExample) | ||
| JP2018514209A5 (enExample) | ||
| FI3527070T3 (fi) | Humanisoituja kevytketjuhiiriä | |
| FI2968461T3 (fi) | Fuusioproteiineja, jotka käsittävät pdgf:ää ja vegf:ää sitovia osia, ja menetelmiä niiden käyttämiseksi | |
| FI2838548T3 (fi) | HLA:n luokan II puutteelliset solut, HLA:n luokan II puutteelliset solut, jotka kykenevät ilmentämään HLA:n luokan II proteiineja, ja niiden käytöt | |
| JP2018528786A5 (enExample) | ||
| JP2023550998A5 (enExample) | ||
| JP2014503198A5 (enExample) | ||
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| IL309260B1 (en) | Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced complement binding | |
| S. Smith et al. | Antibody library display on a mammalian virus vector: combining the advantages of both phage and yeast display into one technology |